17 citations
,
January 2019 in “Journal of cancer” This study found that the medicinal formula YH0618 may reduce toxicity from the chemotherapy drug doxorubicin, improving side effects like hair loss and organ damage, while maintaining its anti-cancer effects.
4 citations
,
December 2019 in “Trials” This study aims to evaluate the effectiveness of YH0618 granules in preventing chemotherapy-induced hair loss in breast cancer patients through a randomized, double-blind, multi-center clinical trial, focusing on potential mechanisms related to kidney deficiency as understood in Chinese Medicine. Results are not yet reported.
This animal study found that YH0618 may alleviate doxorubicin-induced alopecia and affects proteins like keratin and Smad3, suggesting potential therapeutic targets. The researchers analyzed protein expression changes to understand YH0618's effects in treating chemotherapy-related hair loss.
October 2019 in “Research Square (Research Square)” This study will investigate the efficacy of YH0618 granules on reducing chemotherapy-induced hair loss in breast cancer patients, focusing on potential mechanisms related to kidney deficiency, with outcomes not yet reported.
October 2019 in “Research Square (Research Square)” This study aims to evaluate the efficacy of the traditional Chinese medicine YH0618 granule for reducing chemotherapy-induced hair loss in breast cancer patients through a double-blind, randomized clinical trial, assessing hair loss progression and improving quality of life markers compared to a placebo.